Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by ChupacabraBuenoon May 19, 2015 12:42pm
133 Views
Post# 23741299

RE:RE:RE:RE:It's not about Tweed vs. Bedrocan Vs. Mettrum vs. also rans-

RE:RE:RE:RE:It's not about Tweed vs. Bedrocan Vs. Mettrum vs. also rans-Hi Quanadien, I haven't tried to really get my head around the MMJ licensing process. Licensing is a risk factor, with the government being involved. But if TWD could actually sell the quantity that it is already licensed for, revenue would be well into the tens of millions of dollars. So to a large degree it has already cleared the licensing hurdle - and is free to sell what it can. That's why I'm keen to know how the injunction & appeal are likely to be resolved. It seems like the next challenge for industry leaders like TWD will not be getting sufficient licensing or production, but sufficient sales in a market that is still dominated by pre-MMPR sources of supply. And if sales growth is stifled, than the period of negative earnings is prolonged, leading to the concern that you raised that share dilution might be required. The MMPR industry has great potential, but the injunction has thrown a spanner in the spokes. Sorry I couldn't be more informative re. the licensing process - I expect others on this board have considerable knowledge in that regard. -GLTA
Bullboard Posts